このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

中等度から重度の上部顔面線を持つ成人参加者におけるIPN10200の安全性と有効性を評価するための研究 (LANTIC)

2026年10月2日 更新者:Ipsen

成人の中等度から重度の上部顔面線の外観の改善におけるIPN10200の安全性と有効性を評価するためのフェーズIb / II、多施設、二重盲検、無作為化、プラセボ対照、用量漸増および用量設定研究

The purpose of this study is to assess the safety and efficacy profile of increasing doses of Corabotase (also known as IPN10200) in comparison to placebo, with the aim to discover the doses(s) that offer the best efficacy/safety profile when used for the treatment of moderate to severe Upper Facial Lines.

This study will be conducted in three stages. The full study (including all stages) will have a maximum 727 participants.

Stage 1 (phase Ib & II)

  • Step 1 (Phase Ib): a dose-escalation first-in-human step in participants with moderate to severe Glabellar Lines (GL)
  • Step 2 (Phase II): dose ranging step in participants with moderate to severe GL as compared with Dysport
  • Step 3 (Phase II): dose finding step in participants with moderate to severe GL as compared with Dysport, followed by an open label (OL) phase for the highest dose cohort to assess the long-term safety and efficacy of Corabotase. In the OL phase, participants may receive repeat administrations of Corabotase for up to three additional cycles (up to four treatment cycles in total during the study).

Stage 2 (phase II) - An evaluation of efficacy and safety of Corabotase in one of the following regions: GL + forehead lines (FHL), forehead lines (FHL) or lateral canthal lines (LCL)

Stage 3 (phase II)

- A safety and efficacy evaluation of Corabotase in all three regions (GL, FHL and LCL)

調査の概要

状態

積極的、募集していない

条件

介入・治療

研究の種類

介入

入学 (推定)

727

段階

  • フェーズ2
  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

      • Berlin、ドイツ、13353
        • CRS Clinical Research Services Berlin GMBH
      • Berlin、ドイツ
        • Interdisciplinary Study Association
      • Darmstadt、ドイツ
        • ROSENPARK RESEARCH GmbH
      • Düsseldorf、ドイツ
        • Privatpraxis Dr. Hilton & Partner
      • Hamburg、ドイツ
        • Fachbereich Chemie Institut für Biologie und Molekularbiologie Studiengang Kosmetikwissenschaft
      • Mahlow、ドイツ
        • Dermatologische Gemeinschaftspraxis Blankenfelde-Mahlow
    • State of Berlin
      • Kassel、State of Berlin、ドイツ
        • Interdisciplinary Study Association
      • Antibes、フランス
        • MEDITI - Clinique Del Mar
      • Lyon、フランス
        • Aimed S.A.S
      • Paris、フランス
        • Clinique de Chirurgie Esthétique Iéna

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~65年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  1. Participant must be 18 to 65 years of age inclusive, at the time of signing the informed consent.
  2. Moderate or severe (Grade 2 or 3) GL (Stage 1) at maximum contraction at Baseline, as assessed by the ILA using a validated 4-point photographic scale.
  3. Moderate or severe (Grade 2 or 3) GL (Stage 1) at maximum contraction at Baseline, as assessed by the SSA using a validated 4-point categorical scale.
  4. Moderate or severe (Grade 2 or 3) FHL (Stage 2) at maximum contraction and moderate to severe GL at maximum contraction at Baseline or moderate to severe (Grade 2 or 3) LCL (Stage 2) at maximum contraction (Stage as assessed by the ILA using a 4-point photographic scale).
  5. Moderate or severe (Grade 2 or 3) FHL (Stage 3) at maximum contraction and moderate to severe GL at maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL (Stage 3) at maximum contraction (Stage as assessed by the ILA using a 4-point photographic scale).
  6. Moderate or severe (Grade 2 or 3) FHL (Stage 2) at maximum contraction and moderate to severe GL maximum contraction at Baseline or moderate to severe (Grade 2 or 3) LCL (Stage 2) at maximum contraction as assessed by the SSA using a 4-point photographic scale.
  7. Moderate or severe (Grade 2 or 3) FHL (Stage 3) at maximum contraction and moderate to severe GL maximum contraction at Baseline and moderate to severe (Grade 2 or 3) LCL (Stage 3) at maximum contraction, as assessed by the SSA using a 4-point photographic scale.
  8. Dissatisfied or very dissatisfied (Grade 2 or 3) with their lines (Stages 1 to 3) at Baseline, as assessed by the SLS.
  9. Male and female participants (only female for Stage 1/Step 1). Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies
  10. Capable of giving signed informed consent includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
  11. Participant has both the time and the ability to complete the study and comply with study instructions.
  12. Does not reside in an institution by administrative or court order.
  13. Is not a sponsor employee or clinical research unit personnel directly affiliated with the study or is not an immediate family member. Immediate family is defined as a spouse, parent, child or sibling whether biological or legally adopted.

Exclusion Criteria:

  1. An active infection or other skin problems in the upper face including the GL, FHL, and LCL area (e.g. acute acne lesions or ulcers).
  2. A history of eyelid blepharoplasty or brow lift within the past 5 years
  3. A history of facial nerve palsy.
  4. Marked facial asymmetry, ptosis, excessive dermatochalasis, deep dermal scarring, or thick sebaceous skin.
  5. Any known medical condition that may put the participant at increased risk in regard to exposure to BoNT of any serotype (i.e. myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, etc.)
  6. Has COVID-19 illness or a known positive SARS-CoV-2 test (Stage 1), or the presence of any other condition (e.g. neuromuscular disorder or other disorder that could interfere with neuromuscular function)
  7. Previous treatment with any BoNT serotype for Stage 1 / Step 1 or any recent treatment (within the past 9 months prior to baseline) with any BoNT serotype for Stage 1 / Step 2, Stage 1/Step 3, Stages 2 and 3. Participants treated in earlier Stages/Steps of the study must not be included in any later Stages/Steps.
  8. Any prior treatment with permanent fillers in the upper face including the GL, FHL and LCL area.
  9. Any prior treatment with long lasting dermal fillers or any permanent procedures in the upper face inclusion the GL area within the past 3 years and/or skin abrasions/resurfacing (whatever the interventional technic used) within the past 5 years, or photo rejuvenation or skin/vascular laser intervention within the 12 months prior to Baseline.
  10. Any planned facial cosmetic surgery during the study.
  11. Use of concomitant therapy which, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study intervention. Therapy considered necessary for the participant's welfare may be given at the discretion of the investigator.
  12. Use of medications that affect neuromuscular transmission, such as curare-like non depolarising agents, lincosamides, polymyxins, anticholinesterases, aminoglycoside antibiotics and systemic retinoids, within the past 30 days prior to baseline are prohibited or a longer washout period of at least five half-lives might be required, as deemed appropriate by the investigator for longer-acting medications. Topical use of for example aminoglycoside medications or topical retinoids on the face apart from the area of injection would be acceptable.
  13. Use of any experimental device within 30 days or use of any treatment with an experimental drug within five times the documented terminal half-life of the respective drug or its metabolites or if the halflife is unknown within 30 days prior to the start of the study (prior to Baseline) and during the conduct of the study.
  14. Known positive for hepatitis B antigen, or hepatitis C virus antibody, or for human immunodeficiency virus (HIV) or a diagnosis of acquired immunodeficiency syndrome.
  15. Clinically diagnosed significant anxiety disorder, or any other significant psychiatric disorder (e.g. depression) that might interfere with the participant's participation in the study
  16. An inability to substantially lessen GL and/or horizontal forehead rhytids even by physically spreading them apart as determined by the investigator.
  17. Known allergy or hypersensitivity to BoNT or any excipients of IPN10200 or Dusport/Azzalure, or allergy to cow's milk protein.
  18. A history of drug or alcohol abuse
  19. Pregnant women, nursing women, premenopausal women or women of childbearing potential not willing to practice a highly effective form of contraception method
  20. Male participants who are not vasectomized and who have female partners of childbearing potential and are not willing to use condoms with spermicide throughout study participation.
  21. Any uncontrolled systemic disease or other significant medical condition which would be harmful for the participant to be entered into the study or continue participation.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:4倍

武器と介入

参加者グループ / アーム
介入・治療
アクティブコンパレータ:ディスポートグループ(ステージ1 /ステップ2および3のみ)

Single administration of study intervention in stage 1 / step 2 and 3 only

実験的:Corabotase group

Stage 1/Step 1: Several cohorts of participants will be randomized in a ratio of 3:1 (Corabotase:placebo)in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee (DMC) recommendation.

Stage 1/Step 2: parallel dose-ranging manner Stage 1/Step 3: each cohort will include three treatment groups randomised in a ratio of 4:1:1 (Corabotase: placebo:dysport) The decision to escalate to the next dose for each cohort will be based on DMC recommendation .

Stage 2: the dose(s) chosen for administration in each region of the face will be selected on the basis of the intermediate analyses of Stage 1/Step 3. Participants will be randomised for each group in a ratio of 4:4:1 (Corabotase:Corabotase:placebo).

Stage 3: total dose for each region defined in Stages 1 and 2. Participants will be randomised for each group in a ratio of 3:1.

Stage 1: Several different doses will be administrated in a dose-escalation manner.

One single injection will be injected locally into several sites across the glabellar region.

Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.

Stage 3: One single injection will be injected locally into several sites across the upper facial area.

プラセボコンパレーター:Placebo group

Stage 1/Step 1: Several cohorts of participants will be randomized in a ratio of 3:1 in a dose-escalation manner. The decision to escalate to the next dose for each cohort will be based on Data Monitoring Committee (DMC) recommendation.

Stage 1/Step 2: parallel dose-ranging manner Stage 1/Step 3: each cohort will include three treatment groups randomised in a ratio of 4:1:1 (Corabotase:Corabotase: placebo) The decision to escalate to the next dose for each cohort will be based on DMC recommendation.

Stage 2: the dose(s) chosen for administration in each region of the face will be selected on the basis of the intermediate analyses of Stage 1/Step 3. Participants will be randomised for each group in a ratio of 4:4:1 (Corabotase:Corabotase:placebo).

Stage 3: total dose for each region defined in Stages 1 and 2. Participants will be randomised for each group in a ratio of 3:1.(Corabotase:placebo)

Stage 1: One single injection of study intervention will be injected locally into several sites across the glabellar region.

Stage 2: One single injection will be injected locally into several sites across the glabellar, forehead and lateral Canthal regions.

Stage 3: One single injection will be injected locally into several sites across the upper facial area.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Incidence of treatment emergent adverse events (TEAEs) at each dose
時間枠:From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Incidence of serious adverse events (SAEs) at each dose
時間枠:From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Incidence of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)
時間枠:From the baseline to the end of the study (9 months)

At Stage 1/Step 1, Stage 3

From the baseline to the end of the study (9 months)
Response to treatment at Stage 2 for the FHL group
時間枠:At Week 4

Measured by the composite response of ≥ 2-grade improvement on Investigator's Live Assessment (ILA) and subject's self-assessment (SSA) at maximum contraction on the forehead lines:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the Forehead Lines (FHL) at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their FHLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Response to treatment at Stage 2 for the glabellar lines (GL)+ FHL group
時間枠:At Week 4

Measured by the composite response of ≥ 2-grade improvement on ILA and SSA at maximum contraction on the forehead lines (FHL) area:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the GLs and FHLs at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their GLs and FHLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Response to treatment at Stage 2 for the LCL group
時間枠:At Week 4

Measured by the composite response of ≥ 2-grade improvement ILA and SSA at maximum contraction on both sides of the lateral canthal lines (LCL) area:

ILA: a validated 4-point photographic scale to assess the severity and appearance of the LCLs at maximum frown and at rest where 0 is "none" and 3 is "severe"

SSA: a validated 4-point categorical scale to assess the appearance of their LCLs at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

At Week 4
Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs
時間枠:From the baseline to the end of the study (6 years, 5 months)

Double Blind phase. Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (6 years, 5 months)
Percentage of participants with clinically significant Change from baseline in 12-lead Electrocardiogram (ECG) readings
時間枠:From the baseline to the end of the study (6 years, 5 months)

Double Blind phase.

From the baseline to the end of the study (6 years, 5 months)
Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination.
時間枠:From the baseline to the end of the study (6 years, 5 months)

Double Blind phase. Clinically significant changes in facial examination and focused neurological/physical examinations will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (6 years, 5 months)

二次結果の測定

結果測定
メジャーの説明
時間枠
-被験者満足度(SLS)で「非常に満足」または「満足」のスコアによって達成される治療への反応
時間枠:ベースラインから試験終了まで(9ヶ月)
ベースラインから試験終了まで(9ヶ月)
Percentage of participants response to treatment.
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

For all stages. Measured by the composite response of ≥ 2-grade improvement on ILA and SSA for each concerned facial area in each respective stage (GL/LCL/FHL)

ILA: a validated 4-point photographic scale to assess the severity and appearance of the GLs/LCLs/FHLs in each respective stage at maximum frown and at rest where 0 is "no lines are noticeable" and 3 is "lines are extremely pronounced"

SSA: a validated 4-point categorical scale to assess the appearance of their GLs/LCLs/FHLs in each respective stage at maximum frown where 0 is "no wrinkles" and 3 is "severe wrinkles"

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as measured by the reduction of ≥1 grade on the ILA at maximum contraction for each concerned facial area
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants with clinically significant change from baseline in facial and focused neurological/physical examination
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

For all stages. Clinically significant changes in facial examination and focused neurological/physical examinations will be reported. The clinical significance will be graded by the investigator.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as achieved by a score of "none" or "mild" as measured by the ILA at rest on each facial area
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

For all stages

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as measured by the reduction of ≥1 grade on the SSA at maximum contraction for each concerned facial area
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants response to treatment as achieved by a score of "none" or "mild" as measured by the SSA at maximum contraction for each concerned facial area.
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

Stage 2 and Stage 3.

From the baseline to the end of the study (up to 6 years, 5 months)
Duration of treatment response based on ILA and SSA at maximum contraction for each concerned facial area
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Time to onset of treatment response based on subject diary cards to evaluate the appearance of their lines for each concerned facial area
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

For all stages.

From the baseline to the end of the study (up to 6 years, 5 months)
Satisfaction with facial appearance, measured by Facial Appearance Overall scale score on the Face-Q satisfaction scale
時間枠:From the baseline to the end of the study (up to 6 years, 5 months)

Stage 3. Face Q is a participant-reported outcome instrument to evaluate the experience and outcomes of aesthetic facial procedures from the participant's perspective. The Face Q instrument is composed of over 40 scales, covering four domains (Satisfaction with Facial Appearance, Health Related Quality of Life, Adverse Effects, and Process of Care).

From the baseline to the end of the study (up to 6 years, 5 months)
Satisfaction with facial appearance, measured by FACE-Q Short Form Facial Appearance scale score.
時間枠:From the baseline to the end of the study (6 years, 5 months)

Stage 3. The FACE-Q Short Form Facial Appearance scale is a participant-reported outcome instrument. It asks how dissatisfied or satisfied the participant is with their upper facial lines (UFL) (GL+FHL+LCL). The scale ranges from very dissatisfied to very satisfied.

From the baseline to the end of the study (6 years, 5 months)
Incidence, severity and nature of treatment emergent adverse events (TEAEs)
時間枠:From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Incidence, severity and nature of serious adverse events (SAEs)
時間枠:From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Incidence, severity and nature of Adverse Events (AEs) (or SAEs) leading to withdrawals and Adverse Events of Special Interest (AESIs)
時間枠:From baseline to the end of the study (up to 6 years, 5 months)

All stages (except Stage 1/Step 1)

From baseline to the end of the study (up to 6 years, 5 months)
Percentage of Participants With Clinically Significant Changes from baseline in Vital Signs
時間枠:From baseline to the end of the study (6 years, 5 months)

All stages (except Stage 1/Step 1). Clinically significant changes in vital signs will be reported. The clinical significance will be graded by the investigator.

From baseline to the end of the study (6 years, 5 months)
Time between two consecutive injections
時間枠:From baseline to the end of the study (up to 6 years, 5 months)

Stage 1/Step 3 .

From baseline to the end of the study (up to 6 years, 5 months)
Percentage of participants with binding antibodies to IPN10200
時間枠:At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with neutralising antibodies to IPN10200
時間枠:At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with binding antibodies to BontA
時間枠:At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36
Percentage of participants with neutralising antibodies to BontA
時間枠:At Week 4 , Week 24 and Week 36

Stage 1/Step 2, Stage 1/Step 3, Stage 2, and Stage 3

At Week 4 , Week 24 and Week 36

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • スタディディレクター:Ipsen Medical Director、Ipsen

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2021年4月6日

一次修了 (推定)

2027年8月19日

研究の完了 (推定)

2027年8月19日

試験登録日

最初に提出

2021年3月26日

QC基準を満たした最初の提出物

2021年3月26日

最初の投稿 (実際)

2021年3月29日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年10月1日

詳しくは

本研究に関する用語

追加の関連 MeSH 用語

その他の研究ID番号

  • D-FR-10200-002
  • 2024-512782-14-00 (Ctis)

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

はい

IPD プランの説明

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, annotated case report form, statistical analysis plan, and dataset specifications.

Patient level data will be anonymized and study documents will be redacted to protect the privacy of study participants.

IPD 共有時間枠

Where applicable, data from eligible studies are available 6 months after the studied medicine and indication have been approved in the US and/or EU.

IPD 共有アクセス基準

Further details on Ipsen's sharing criteria and process for sharing are available here (https://www.ipsen.com/science/clinical-trials/clinical-data-transparency/).

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。